Biovista combines augmented and artificial intelligence to drive new possibilities for safer, more-precise medicines. See here for more…
Navigating the biological unknown
Biovista Articles
SciBX interviews Biovista’s CMO on Remyelination
Lauren Martz of Nature’s Science Business Exchange (SciBX) interviews Biovista’s Dr Deftereos on “Myelination from neural stem cells”. Read article here.
The role of drug repositioning in future drug development
What role is #drugrepositioning to take in future drug development? Interview of Aris Persidis to Total BioPharma’s Matt Turner 5 April 2012 “I see a very significant role for drug repositioning in current and also future drug development. Not only is it driven by the patent cliff, which is not a singular event but a … Read More
Pharmaceutical Engineering interview with Dr. Aris Persidis
Industry Interview Series: Dr. Aris Persidis, President and Co-founder, Biovista, Inc. Online article in Pharmaceutical Engineering Magazine. With patent expirations looming for many major pharmaceutical companies, drug repositioning has become a matter of intense interest during the past few years. Biovista’s President and Co-founder discusses the basics of drug repositioning and the potential impact it … Read More
Repurposed drugs and your IP strategy
Using examples of drugs and companies, Dr Andreas Persidis gives tips on how to establish a systematic drug repositioning programme. Online article in the Managing Intellectual Property website. In the absence of productive internal R&D sufficient to support growth, current pharmaceutical IP strategies focus on acquiring smaller biotechs with promising assets to bolster larger pharma’s … Read More